Table 2.
Parameter | Aptamer BC 007 | Control 1 | Control 2 | P‐value C1 | P‐value C2 |
---|---|---|---|---|---|
Basic parameters | |||||
Gender (male/female) | 8/6 (57%/43%) | 7/7 (50%/50%) | 9/5 (64%/36%) | 0.705 | 0.699 |
Age (years) | 7.2 ± 2.1 | 6.9 ± 2.3 | 7.3 ± 2.7 | 0.765 | 0.913 |
Weight (kg) | 36.7 ± 6.5 | 37.2 ± 5.8 | 37.3 ± 5.0 | 0.824 | 0.784 |
β1‐AAB (Δ beats/min) |
21 ± 3 | 20 ± 6 | 0.400 | ||
Cardiac treatment | |||||
Pimobendan | 13/14 (93%) | 14/14 (100%) | 14/14 (100%) | 1.000 | 1.000 |
Ramipril | 12/14 (86%) | 12/14 (86%) | 13/14 (93%) | 1.000 | 1.000 |
Sotalol | 5/14 (36%) | 4/14/28%) | 5/14 (36%) | 1.000 | 1.000 |
Mexiletine | 1/14 (7%) | 0/14 (0%) | 0/14 (0%) | 1.000 | 1.000 |
Flecainide | 5/14 (36%) | 4/14 (28%) | 2/14 (14%) | 1.000 | 0.385 |
Amiodarone | 2/14 (14%) | 4/14 (28%) | 4/14 (28%) | 0.648 | 0.648 |
Furosemide | 1/14 (7%) | 0/14 (0%) | 0/14 (0%) | 1.000 | 1.000 |
Dogs treated with antiarrhythmics | 7/14 (50%) | 8/14 (57%) | 9/14 (64%) | 0.705 | 0.445 |
Time since start of pimobendan (months) | 4.6 ± 4.9 | 3.3 ± 1.6 | 4.8 ± 2.0 | 0.352 | 0.854 |
Echocardiography | |||||
EDVI (mL/m2) | 117 ± 33 | 108 ± 17 | 120 ± 33 | 0.349 | 0.814 |
ESVI (mL/m2) | 81 ± 31 | 69 ± 16 | 80 ± 28 | 0.218 | 0.883 |
LA:Ao | 1.36 ± 0.28 | 1.38 ± 0.09 | 1.36 ± 0.21 | 0.845 | 0.952 |
24 h Holter ECG | |||||
VPCs per 24 h | 721 ± 1019 | 1821 ± 3159 | 503 ± 892 | 0.226 | 0.554 |
FR of VPCs (b.p.m.) | 259 ± 36 | 270 ± 49 | 248 ± 42 | 0.510 | 0.455 |
VTach per 24 h | 0.14 ± 0.54 | 2.21 ± 6.66 | 0.14 ± 0.54 | 0.256 | 1.000 |
Number of dogs with VTach | 1/14 (7%) | 3/14 (21%) | 1/14 (7%) | 0.596 | 1.000 |
Δ PR/min, change in pulse rate per minute; b.p.m., beats per minute; EDVI, end‐diastolic volume index; ESVI, end‐systolic volume index; FR, the fastest rate of all VPCs; LA:Ao, left atrial dimension to the aortic annulus dimension; VPCs, ventricular premature complexes; VTach, number of ventricular tachycardia.